bioecon Member area
Technology · Health & biomedicine / Regenerative & personalized medicine

Viro-Immunotherapeutics

Recombinant tumor-selective oncolytic viruses (herpes simplex, vesicular stomatitis, adenoviruses) engineered with genetic deletions restricting replication to p53/Rb-deficient cancer cells while armed with GM-CSF, IL-12, or BiTE payloads to provoke catastrophic in-situ tumor lysis and systemic neoantigen immunity.

Medicine & Pharmaceuticals Industrial Manufacturing Maturity 7/9 Risk: medium Pharma & biologics Biomanufacturing & Bio-industrial Production CH · EU · US · CN verified 2026-11-22 · 1 Sources (0 independent)

1 · What it gives

Viro-Immunotherapeutics represents a cornerstone in global infectious disease defense and preventive immunotherapy, encompassing multivalent polysaccharide-protein conjugates, viral vectors, therapeutic cancer vaccines, and anti-infective phage platforms. By converting poorly immunogenic T-cell-independent antigens into robust, durable T-cell-dependent immune responses with immunological memory, the technology has eradicated major bacterial pathogens and provides proactive pandemic preparedness. Industrial bioprocess engineering coordinates bacterial/viral propagation, chemical activation, carrier protein conjugation, and immunological adjuvant compounding.

The operational spectrum encompasses large-scale microbial fermentation (e.g., Streptococcus pneumoniae, Neisseria meningitidis, or engineered E. coli), continuous lysis, and polysaccharide purification via tangential flow filtration. Polysaccharide chains undergo size-controlled microfluidic homogenization before cyanylation (using CDAP) or periodate activation, followed by covalent coupling to detoxified carrier proteins (such as CRM197, tetanus toxoid, or outer membrane vesicles). Purification utilizes 100–300 kDa ultrafiltration and size-exclusion chromatography, yielding conjugate purities >95% with free unconjugated polysaccharide <5%, followed by sterile formulation with advanced adjuvant systems (alum, MF59, QS-21).

The key directions of this technology are:

  1. Controlled Polysaccharide Activation for Viro-Immunotherapeutics: Implementing CDAP (1-cyano-4-dimethylaminopyridinium tetrafluoroborate) cyanylation to activate hydroxyl groups without depolymerizing native polysaccharide epitopes.
  2. Carrier Protein Conjugation & Cross-Linking: Coupling activated antigens to recombinant CRM197 or tetanus toxoid under controlled stoichiometry to maximize T-cell-dependent B-cell priming.
  3. Advanced Adjuvant Emulsion & Liposome Formulation: Compounding antigens with squalene-in-water nanoemulsions (MF59) or liposomal saponin combinations (AS01) to induce broad mucosal and systemic titers.
  4. Lyophilized Cold-Chain Independence: Developing spray-freeze-dried or trehalose-stabilized solid formulations maintaining vaccine potency at ambient temperatures (up to 40°C) for global distribution.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: High-Density Microbial Fermentation           │
│  (Pathogen culture, fed-batch, dissolved oxygen control│
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Lysis, Benzonase Digestion & TFF Extraction   │
│  (Enzymatic DNA/RNA clearance, 100-300 kDa diafiltr.)  │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Chemical Activation & Carrier Conjugation     │
│  (CDAP activation, CRM197 coupling, free antigen <5%)  │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Size-Exclusion & Hydrophobic Interaction Pur. │
│  (Separation of high-MW conjugates, endotoxin removal) │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Adjuvant Compounding & Sterile Fill-Finish    │
│  (Alum/nanoemulsion blending, 0.22 um filter, vials)   │
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Pathogen Strain Cultivation & BankingHigh-density fermentation of bacterial or viral production strains under Biosafety Level (BSL-2/3) containment.In: Cryopreserved seed stock, defined animal-free media, automated bioreactors.
Out: High-titer crude harvest broth containing target polysaccharide/antigen.
Cell Lysis & Primary PurificationDetergent or mechanical microfluidic cell disruption followed by Benzonase nuclease treatment to digest host nucleic acids.In: Crude harvest, Benzonase endonuclease, depth filtration cassettes.
Out: Clarified antigen-rich lysate free of genomic DNA contaminants.
Polysaccharide Activation & ConjugationControlled activation using CDAP or sodium periodate, followed by covalent linkage to CRM197 or recombinant protein carriers.In: Purified polysaccharide, carrier protein, CDAP cyanylating reagent.
Out: Covalently linked macromolecular conjugate reaction pool.
Conjugate Polishing & Free Antigen RemovalTangential flow ultrafiltration (300 kDa PES) and hydrophobic interaction chromatography removing unconjugated free polysaccharide.In: Crude conjugate, ammonium sulfate buffer, ultrafiltration cassettes.
Out: Purified conjugate drug substance with free polysaccharide < 5%.
Adjuvant Blending & Sterile Vial FillingCompounding with aluminum hydroxide or squalene emulsions, terminal sterile 0.22 um filtration, and automated filling into glass vials.In: Conjugate drug substance, adjuvant suspension, USP Type I vials.
Out: Final sterile multi-dose or single-dose vaccine product.

Cross-cutting technologies of the sector:

  • Multi-Angle Light Scattering (SEC-MALS): Absolute molecular weight profiling determining size distribution and polydispersity of high-molecular-weight vaccine conjugates.
  • Endotoxin & Pyrogen Testing (LAL / MAT): Recombinant factor C fluorometry and monocyte activation testing guaranteeing bacterial endotoxin levels strictly below pharmacopeial limits.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 4 steps

  1. 1
    Viral genome attenuation
    Deleting neurovirulence and immune-evasion genes (e.g. gamma-34.5 in HSV-1) to ensure selective lysis of malignant cells with zero pathogenicity in healthy neurons.
  2. 2
    Immunostimulatory transgene arming
    Inserting expression cassettes encoding human GM-CSF, IL-12, or anti-PD-L1 single-chain antibodies into the viral genome under strong viral promoters.
  3. 3
    Intratumoral or systemic delivery
    Formulating oncolytic vectors for direct ultrasound-guided intratumoral injection or shielding with polymers to allow intravenous systemic administration.
  4. 4
    In-situ tumor lysis and abscopal effect
    Triggering extensive immunogenic necroptosis of the injected tumor nodule and inducing durable systemic T-cell mediated regression of untreated distant metastases.

4 · Who delivers

Matched suppliers (matched automatically)

NovartisSwitzerlandProduceractive
Esco AsterSingaporeServices / consultingactive
ORF GeneticsIcelandProduceractive
AGC BiologicsUnited StatesProduceractive
GenScript ProBio / GenscriptChinaServices / consultingactive
AstraZenecaUnited KingdomProduceractive
Spiber Technologies ABSwedenResearch / RTOactive
LoopwormIndiaProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Novartis🇨🇭 SwitzerlandInnovative Medicines & Targeted TherapiesIndustrial scalable manufacturing & QbD validationcommercial
Roche / Genentech🇨🇭 SwitzerlandBiopharma Discovery & Diagnostic PlatformsIndustrial scalable manufacturing & QbD validationcommercial
Molecular🇺🇸 United StatesSpecialized Modality & Process PlatformIndustrial scalable manufacturing & QbD validationcommercial
John Bell🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
Viromissile, .🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
Tilt Biotherapeutics🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
CanVirex🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical

5 · Rules & route to market

United States

FDA CBER oversight, BARDA pandemic funding, and CDC schedules#

  • FDA CBER Vaccine Standards: Strict clinical efficacy, lot-to-lot consistency, and potency assay requirements under CBER biologic regulations.
  • BARDA Strategic National Stockpile: Federal emergency preparedness funding supporting rapid-response vaccine manufacturing and surge capacity.
  • CDC Advisory Committee (ACIP) Recommendations: Rapid pediatric and adult immunization schedule adoption driving nationwide commercial scale.

European Union

EMA centralized evaluation, WHO collaborative hubs, Swiss quality#

  • European Vaccine Manufacturing Hubs: Long-established commercial production campuses across France, Belgium, and Germany supplying global immunization campaigns.
  • EMA Official Control Authority Batch Release (OCABR): Independent national control laboratory testing of each commercial batch prior to market release.
  • Global Health Initiatives: CEPI and Gavi partnerships headquartered in Geneva driving development of disease-X prototype platforms and equitable access.

China

National Immunization Program, NMPA pre-qualification, mega-capacity#

  • NMPA Priority Review & National Procurement: Fast-track clinical review and volume-based procurement driving massive scale for innovative vaccines.
  • Global WHO Pre-Qualification (PQ): Top Chinese manufacturers (Sinopharm, Sinovac, CanSino) achieving WHO pre-qualification for international supply.
  • High-Capacity Vaccine Centers: State-of-the-art biomanufacturing campuses in Beijing, Wuhan, and Shanghai with annual capacities exceeding billions of doses.

6 · Money: tenders & grants

7 · Tech stack & innovations

  1. Antigenic Carrier Architecture in Viro-Immunotherapeutics:
    • Utilizes non-toxic diphtheria toxin mutant CRM197 or tetanus toxoid containing dense CD4+ T-cell helper epitopes.
    • Triggers robust germinal center B-cell activation, immunoglobulin class switching to IgG1/IgG3, and long-term immunological memory.
  2. Controlled CDAP Cyanylation Chemistry:
    • 1-cyano-4-dimethylaminopyridinium tetrafluoroborate converts polysaccharide hydroxyls into cyanate esters under mild conditions (pH 9.0).
    • Forms stable isourea covalent bonds with carrier protein lysine residues while eliminating toxic cyanogen bromide byproducts.
  3. Ultra-High-Molecular-Weight Tangential Flow Filtration:
    • 300 kDa cut-off polyethersulfone membranes operated under controlled transmembrane pressure (<1.0 bar).
    • Delivers complete separation of heavy conjugated molecules (>1,000 kDa) from unreacted low-molecular-weight free polysaccharides.

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22